Prolactinomas, Cushing's disease and acromegaly: Debating the role of medical therapy for secretory pituitary adenomas

BMC Endocrine Disorders

Volumn 10, Issue , 2010, Pages

  Biller, Beverly M K ^a   Colao, Annamaria ^b   Petersenn, Stephan ^c   Bonert, Vivien S ^d   Boscaro, Marco ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BIM 23 A 760; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ETOMIDATE; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PERGOLIDE; PIOGLITAZONE; QUINAGOLIDE; RETINOIC ACID; ROSIGLITAZONE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ACNE; ACROMEGALY; ADRENAL GLAND; ADRENALECTOMY; AMENORRHEA; APOPTOSIS; ATAXIA; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; CUSHING DISEASE; CYTOREDUCTIVE SURGERY; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EDEMA; ENDOCRINE SURGERY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FOLLOW UP; GALACTORRHEA; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL DISEASE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GYNECOMASTIA; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART VALVE REGURGITATION; HIGH RISK PATIENT; HIRSUTISM; HUMAN; HYDROCORTISONE RELEASE; HYPERPIGMENTATION; HYPERPROLACTINEMIA; HYPERTENSION; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; IMPOTENCE; IN VITRO STUDY; INCIDENCE; INFERTILITY; LIBIDO DISORDER; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE INFERTILITY; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; META ANALYSIS; MORBIDITY; MORTALITY; MULTIMODALITY CANCER THERAPY; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NELSON SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PARKINSON DISEASE; PATIENT CARE; PREVALENCE; PROGNATHIA; PROLACTIN RELEASE; PROLACTINOMA; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTON RADIATION; RADIATION; RASH; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; SELLA TURCICA TUMOR; SKULL SURGERY; STEREOTACTIC BODY RADIATION THERAPY; STRIA; SURGEON; SURGICAL APPROACH; SURGICAL RISK; SWEATING; SYSTEMATIC REVIEW; THERAPY RESISTANCE; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION; TUMOR VOLUME; VAGINAL DRYNESS; VALVULAR HEART DISEASE; VISUAL FIELD DEFECT; WEIGHT GAIN;

EID: 77952124423     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-10-10     Document Type: Review

References (128)

1. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer 2001, 8:287-305. 10.1677/erc.0.0080287, 11733226.
2. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004, 101:613-619. 10.1002/cncr.20412, 15274075.
3. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91:4769-4775. 10.1210/jc.2006-1668, 16968795.
4. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27:485-534. 10.1210/er.2005-9998, 16705142.
5. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998, 352:1455-1461. 10.1016/S0140-6736(98)03356-X, 9808008.
6. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003, 6:19-27. 10.1023/A:1026225625897, 14674720.
7. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000, 85:2247-2252. 10.1210/jc.85.6.2247, 10852458.
8. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP, Wardlaw SL. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000, 85:8-13. 10.1210/jc.85.1.8, 10634356.
9. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985, 60:698-705. 10.1210/jcem-60-4-698, 3882737.
10. Schlechte JA. Long-term management of prolactinomas. J Clin Endocrinol Metab 2007, 92:2861-2865. 10.1210/jc.2007-0836, 17682084.
11. Colao A, Di Sarno A, Cappabianca P, di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003, 349:2023-2033. 10.1056/NEJMoa022657, 14627787.
12. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996, 14:228-238. 10.2165/00002018-199614040-00003, 8713691.
13. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007, 356:29-38. 10.1056/NEJMoa062222, 17202453.
14. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356:39-46. 10.1056/NEJMoa054830, 17202454.
15. Colao A, Galderisi M, Di SA, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008, 93:3777-3784. 10.1210/jc.2007-1403, 18682513.
16. Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM. Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008, 93:3348-3356. 10.1210/jc.2007-2658, 18559921.
17. Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, ris-Jilwan N, Houde G, Serri O. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2008, 12:153-157.
18. Devin JK, Lakhani VT, Byrd BF, Blevins LS. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr Pract 2008, 14:672-677.
19. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf) 2009, 70:104-108. 10.1111/j.1365-2265.2008.03458.x, 19128367.
20. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008, 159:R11-R14. 10.1530/EJE-08-0365, 18625690.
21. Bogazzi F, Buralli S, Manetti L, Raffaelli V, Cigni T, Lombardi M, Boresi F, Taddei S, Salvetti A, Martino E. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 2008, 62:1864-1869. 10.1111/j.1742-1241.2008.01779.x, 18462372.
22. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008, 159:1-5. 10.1530/EJE-08-0213, 18456868.
23. Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM, Miller KK, Utz A, Grinspoon S, Lawson EA, Klibanski A. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf) 2010, 72:53-58. 10.1111/j.1365-2265.2009.03608.x, 19508591.
24. Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest 2008, 31:1119-1123.
25. Cannavo S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 1999, 22:306-309.
26. Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. Ann Med 1998, 30:452-459. 10.3109/07853899809002486, 9814831.
27. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003, 148:325-331. 10.1530/eje.0.1480325, 12611613.
28. Olafsdottir A, Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2006, 2:552-561. 10.1038/ncpendmet0290, 17024154.
29. Hofland LJ, Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, Lely AJ, Beckers A, Lamberts SW. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004, 89:1577-1585. 10.1210/jc.2003-031344, 15070915.
30. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005, 28:21-27.
31. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007, 148:6107-6114. 10.1210/en.2007-0378, 17656461.
32. Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 2008, 158:595-603. 10.1530/EJE-07-0806, 18426817.
33. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593-5602. 10.1210/jc.2003-030871, 14671138.
34. Findling JW, Raff H. Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab 2006, 91:3746-3753. 10.1210/jc.2006-0997, 16868050.
35. Biering H, Knappe G, Gerl H, Lochs H. Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 2000, 27:27-31. 10.1046/j.1563-2571.2000.00106.x, 10812460.
36. Atkinson AB, Kennedy A, Wiggam MI, McCance DR, Sheridan B. Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005, 63:549-559. 10.1111/j.1365-2265.2005.02380.x, 16268808.
37. Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M. Treatment of ACTH-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008, 93:2454-2462. 10.1210/jc.2007-2734, 18413427.
38. Oyesiku NM. Stereotactic radiosurgery for Cushing disease: a review. Neurosurg Focus 2007, 23:E14. 10.3171/FOC-07/12/E14, 18081479.
39. Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1996, 81:2647-2652. 10.1210/jc.81.7.2647, 8675592.
40. Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 2007, 92:172-179. 10.1210/jc.2006-1328, 17062771.
41. Nelson DH, MEAKIN JW, THORN GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med 1960, 52:560-569.
42. Miller JW, Crapo L. The medical treatment of Cushing's syndrome. Endocr Rev 1993, 14:443-458.
43. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 2008, 158:91-99. 10.1530/EJE-07-0514, 18166822.
44. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clin Endocrinol (Oxf) 1991, 35:169-178. 10.1111/j.1365-2265.1991.tb03517.x, 1657460.
45. Schteingart DE, Tsao HS, Taylor CI, McKenzie A, Victoria R, Therrien BA. Sustained remission of Cushing's disease with mitotane and pituitary irradiation. Ann Intern Med 1980, 92:613-619.
46. Luton JP, Mahoudeau JA, Bouchard P, Thieblot P, Hautecouverture M, Simon D, Laudat MH, Touitou Y, Bricaire H. Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases. N Engl J Med 1979, 300:459-464.
47. Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK. Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome. J Clin Endocrinol Metab 2001, 86:4104-4108. 10.1210/jc.86.9.4104, 11549633.
48. Greening JE, Brain CE, Perry LA, Mushtaq I, Sales MJ, Grossman AB, Savage MO. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res 2005, 64:140-143. 10.1159/000088587, 16192738.
49. Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing's syndrome and peritonitis. J Clin Endocrinol Metab 1998, 83:3542-3544. 10.1210/jc.83.10.3542, 9768661.
50. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P. Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004, 151:173-178. 10.1530/eje.0.1510173, 15296471.
51. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002, 8:1281-1287. 10.1038/nm784, 12379847.
52. Emery MN, Leontiou C, Bonner SE, Merulli C, Nanzer AM, Musat M, Galloway M, Powell M, Nikookam K, Korbonits M, Grossman AB. PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf) 2006, 65:389-395. 10.1111/j.1365-2265.2006.02610.x, 16918962.
53. Pecori F, Scaroni C, Arvat E, Martin M, Giordano R, Albiger N, Leao AA, Picu A, Mantero F, Cavagnini F. Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clin Endocrinol (Oxf) 2006, 64:219-224. 10.1111/j.1365-2265.2006.02452.x, 16430724.
54. Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endocrinol Metab 2005, 90:1340-1346. 10.1210/jc.2004-1746, 15585550.
55. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471. 10.1056/NEJMoa072761, 17517853.
56. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004, 89:2452-2462. 10.1210/jc.2003-030837, 15126577.
57. Adams EF, Ashby MJ, Brown SM, White MC, Mashiter K. Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin Endocrinol (Oxf) 1981, 15:479-484. 10.1111/j.1365-2265.1981.tb00691.x, 6276051.
58. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001, 14:329-336. 10.1385/ENDO:14:3:329, 11444429.
59. Pivonello R, De Martino MC, Cappabianca P, De LM, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2008, 94:223-230. 10.1210/jc.2008-1533, 18957500.
60. Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, Petersenn S. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland. Horm Metab Res 2005, 37:722-728. 10.1055/s-2005-921092, 16372224.
61. Woodhouse NJ, Dagogo-Jack S, Ahmed M, Judzewitsch R. Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing's syndrome. Am J Med 1993, 95:305-308. 10.1016/0002-9343(93)90283-U, 8396322.
62. Invitti C, De Martin M, Brunani A, Piolini M, Cavagnini F. Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin). Clin Endocrinol (Oxf) 1990, 32:275-281. 10.1111/j.1365-2265.1990.tb00867.x, 2160871.
63. Ambrosi B, Bochicchio D, Fadin C, Colombo P, Faglia G. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 1990, 13:257-261.
64. Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM. Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol 1999, 157:75-85. 10.1016/S0303-7207(99)00161-6, 10619399.
65. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80(Suppl 1):47-50. 10.1159/000080741, 15477717.
66. Hofland LJ, Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SWJ. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005, 152:645-654. 10.1530/eje.1.01876, 15817922.
67. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 2006, 91:4482-4488. 10.1210/jc.2006-1245, 16940446.
68. Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumour cells. Am J Physiol Endocrinol Metab 2005, 289:E278-E287. 10.1152/ajpendo.00004.2005, 15769796.
69. Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 2008, 286:69-74. 10.1016/j.mce.2007.09.006, 17977644.
70. Silva AP, Schoeffter P, Weckbecker G, Bruns C, Schmid HA. Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. Eur J Endocrinol 2005, 153:R7-R10. 10.1530/eje.1.01998, 16131595.
71. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, Snyder P, Tabarin A, Biller BM, Findling J, Melmed S, Darby CH, Hu K, Wang Y, Freda PU, Grossman AB, Frohman LA, Bertherat J. Treatment of pituitary dependent Cushing's disease with the multi-receptor ligand somatostatin analog pasireotide (SOM230): A multicenter, phase II trial. J Clin Endocrinol Metab 2009, 94:115-122. 10.1210/jc.2008-1008, 18957506.
72. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, Lelij AJ, de Herder WW, Lamberts SW, Hofland LJ. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009, 94:1118-1124. 10.1210/jc.2008-2101, 19141584.
73. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 2001, 86:3568-3573. 10.1210/jc.86.8.3568, 11502780.
74. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do CC, Morange I, Pico A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B. Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol 2009, 160:1003-1010. 10.1530/EJE-09-0098, 19289534.
75. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E. Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006, 147:4438-4444. 10.1210/en.2006-0414, 16740975.
76. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355:2558-2573. 10.1056/NEJMra062453, 17167139.
77. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994, 41:95-102. 10.1111/j.1365-2265.1994.tb03789.x, 8050136.
78. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83:2730-2734. 10.1210/jc.83.8.2730, 9709939.
79. Clayton RN. New developments in the management of acromegaly. Should we achieve absolute biochemical cure?. J Endocrinol 1997, 155(Suppl 1):S23-S29.
80. Melmed S. Acromegaly and cancer: not a problem?. J Clin Endocrinol Metab 2001, 86:2929-2934. 10.1210/jc.86.7.2929, 11443145.
81. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89:667-674. 10.1210/jc.2003-031199, 14764779.
82. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E. A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 2005, 90:4081-4086. 10.1210/jc.2004-1381, 15886256.
83. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005, 153:737-740. 10.1530/eje.1.02036, 16322377.
84. Christy NP. Choosing the best treatment for acromegaly. JAMA 1982, 247:1320. 10.1001/jama.247.9.1320, 6121067.
85. AACE Acromegaly Guidelines Task Force AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004, 10:213-225. AACE Acromegaly Guidelines Task Force.
86. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005, 152:379-387. 10.1530/eje.1.01863, 15757854.
87. Jenkins PJ, Bates P, Carson MN, Stewart PM, Wass JA. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006, 91:1239-1245. 10.1210/jc.2005-1616, 16403824.
88. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, Farabola M, Loli P, Beck-Peccoz P, Arosio M. Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. J Clin Endocrinol Metab 2003, 88:3105-3112. 10.1210/jc.2002-021663, 12843150.
89. Castinetti F, Nagai M, Dufour H, Kuhn JM, Morange I, Jaquet P, Conte-Devolx B, Regis J, Brue T. Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol 2007, 156:91-98. 10.1530/eje.1.02323, 17218730.
90. Jagannathan J, Sheehan JP, Pouratian N, Laws ER, Steiner L, Vance ML. Gamma knife radiosurgery for acromegaly: outcomes after failed transsphenoidal surgery. Neurosurgery 2008, 62:1262-1269. 10.1227/01.neu.0000333297.41813.3d, 18824992.
91. Petit JH, Biller BM, Coen JJ, Swearingen B, Ancukiewicz M, Bussiere M, Chapman P, Klibanski A, Loeffler JS. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract 2007, 13:726-734.
92. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004, 114:349-356. 484973, 15286801.
93. Nishina Y, Takano K, Yasufuku-Takano J, Teramoto A, Fujita T. Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells. Endocr J 2005, 52:775-779. 10.1507/endocrj.52.775, 16410672.
94. Freda PU. Pegvisomant therapy for acromegaly. Exp Rev Endcrinol Metab 2006, 1:489-498.
95. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002, 87:3013-3018. 10.1210/jc.87.7.3013, 12107192.
96. Freda PU, Katznelson L, Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90:4465-4473. 10.1210/jc.2005-0260, 15886238.
97. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, Pico AM, Valimaki M, Zgliczynski W. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002, 87:99-104. 10.1210/jc.87.1.99, 11788630.
98. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998, 83:3034-3040. 10.1210/jc.83.9.3034, 9745397.
99. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002, 56:65-71. 10.1046/j.0300-0664.2001.01438.x, 11849248.
100. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf) 2004, 60:375-381. 10.1111/j.1365-2265.2004.01992.x, 15009004.
101. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001, 86:2779-2786. 10.1210/jc.86.6.2779, 11397887.
102. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G. First-line octreotide-LAR therapy induces tumor shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006, 64:342-351. 10.1111/j.1365-2265.2006.02467.x, 16487447.
103. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Beneficial effect of dose escalation of Octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007, 157:579-587. 10.1530/EJE-07-0383, 17984237.
104. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006, 91:1397-1403. 10.1210/jc.2005-2347, 16449332.
105. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 2005, 63:168-175. 10.1111/j.1365-2265.2005.02317.x, 16060910.
106. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007, 66:859-868. 10.1111/j.1365-2265.2007.02825.x, 1974838, 17465997.
107. Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90:1856-1863. 10.1210/jc.2004-1093, 15613435.
108. Hoek J, de Herder WW, Feelders RA, Lely AJ, Uitterlinden P, Boerlin V, Bruns C, Poon KW, Lewis I, Weckbecker G, Krahnke T, Hofland LJ, Lamberts SW. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004, 89:638-645. 10.1210/jc.2003-031052, 14764775.
109. Hoek J, Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 2005, 63:176-184. 10.1111/j.1365-2265.2005.02322.x, 16060911.
110. Farrall A, Glusman JE, Ruffin M, Petersenn S. Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: preliminary 6-month results from a Phase II extension study. Endocrine Abstracts 2008, 16:OC1.4.
111. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J Clin Endocrinol Metab 2010,
112. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83:374-378. 10.1210/jc.83.2.374, 9467544.
113. Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da RN, Branca V, Oppizzi G, Gelli D. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?. Eur J Endocrinol 1998, 139:516-521. 10.1530/eje.0.1390516, 9849816.
114. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004, 61:209-215. 10.1111/j.1365-2265.2004.02082.x, 15272916.
115. Culler MD, Dong JZ, Taylor JE, et al. The somatostatin-dopamine chimeric molecule, BIM-23A760, does not induce the insulin/glycemic effects observed with individual somatostatin or dopamine agonists in cynomolgus monkeys (Macaca fascicularis). 12th meeting of the European Neuroendocrine Association, abstract OC2 11 2006,
116. Jehle S, Reyes CM, Sundeen RE, Freda PU. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 2005, 90:1588-1593. 10.1210/jc.2004-1967, 15585549.
117. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342:1171-1177. 10.1056/NEJM200004203421604, 10770982.
118. Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-1759. 10.1016/S0140-6736(01)06844-1, 11734231.
119. Feenstra J, de Herder WW, ten Have SM, Beld AW, Feelders RA, Janssen JA, Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365:1644-1646. 10.1016/S0140-6736(05)63011-5, 15885297.
120. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, Lely AJ. Long-term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. J Clin Endocrinol Metab 2007, 92:4598-4601. 10.1210/jc.2007-1234, 17895318.
121. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, Lely AJ. Quality of Life in Acromegalic Patients during Long-Term Somatostatin Analog Treatment with and without Pegvisomant. J Clin Endocrinol Metab 2008, 93:3853-3859. 10.1210/jc.2008-0669, 18647806.
122. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab 2008, 93:3515-3518. 10.1210/jc.2008-0833, 18611977.
123. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146:707-716. 10.1530/eje.0.1460707, 11980628.
124. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003, 24:28-47. 10.1210/er.2000-0001, 12588807.
125. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005, 153:135-141. 10.1530/eje.1.01950, 15994755.
126. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999, 20:157-198. 10.1006/frne.1999.0183, 10433861.
127. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Grasso LF, Lombardi G. Growth hormone-secreting tumor shrinkage after 3 months of octreotide-LAR therapy predicts the response at 12 months. J Clin Endocrinol Metab 2008, 93:3436-3442. 10.1210/jc.2008-0424, 18593770.
128. Colao A, Cappabianca P, Caron P, De ME, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) 2009, 70:757-768. 10.1111/j.1365-2265.2008.03441.x, 19178516.